Background: SERPINB10 is a serine proteinase inhibitor of the ovalbumin like B clade of serpins. It was first discovered in human bone marrow in a search for serpins similar to SerpinB6. SERPINB10 was identified in lymphocytes, and was elevated in chronic myeloid leukemia and chronic myelomonocytic leukemia cells. The monocytic cell lines THP-1 and AML-193 also showed elevated SERPINB10 expression. It is similar to PI-9, also found in blood marrow cells, but SERPINB10 seems to be more restricted in distribution. SERPINB10 has been shown to inhibit thrombin and trypsin in vitro, and to inhibit tumor necrosis factor alpha induced cell death. The mode of action seems similar to SerpinB9, which prevents cell mediated cell death by inhibiting granzyme B, although SERPINB10 has not been implicated in granzyme B inhibition. Most leukemia cells and many tumor cells produce PI-9, leading to speculation that PI-9 may help protect tumor cells from destruction by NK and CTL cells, and this may be true of SERPINB10 as well. Like SerpinB6 and SerpinB8, SERPINB10 lacks a signal sequence, and is found mainly in the cytoplasm and nucleus, although it can be detected outside of cells and in serum. e original sequence described was 397 amino acids in length, with predicted mass of 42.4 kDa and pI of 5.74. A

Description: Rabbit polyclonal to SERPINB10

Immunogen: KLH conjugated synthetic peptide derived from SERPINB10

Specificity:  ·Reacts with Human, Mouse and Rat.

·Isotype: IgG

Application:  ·Western blotting: 1/100-500. Predicted Mol wt: 45 kDa;

·Immunohistochemistry (Paraffin/frozen tissue section): 1/50-200;

·Immunocytochemistry/Immunofluorescence: 1/100;

·Immunoprecipitation: 1/50;

·ELISA: 1/500;

·Optimal working dilutions must be determined by the end user.